Dermatology News and Research

Latest Dermatology News and Research

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Psoriasis link with autoimmune diseases underscored

Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.

8 Jun 2012

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.

8 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Imiquimod and PDT equivalent for superficial basal cell carcinoma

Imiquimod cream and photodynamic therapy for superficial basal cell carcinoma result in near equivalent rates of tumor-free survival after 1 year of treatment, a review shows.

1 Jun 2012

Psoriasis linked to sexual dysfunction in men

Men with psoriasis are at an increased risk for sexual dysfunction, research suggests.

1 Jun 2012

Common pain killers linked to decreased skin cancer risk

Use of nonsteroidal anti-inflammatory drugs is associated with a decreased risk for skin cancer, particularly squamous cell carcinoma and malignant melanoma, study findings indicate.

31 May 2012

Researchers identify new peptide that can block fibrosis of the skin and lungs

A member of the Scleroderma Foundation's Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today.

31 May 2012

Skin transplant surgery safe and effective for patients with vitligo

Henry Ford Hospital dermatologists say skin transplant surgery is safe and effective for restoring skin pigmentation caused by the skin disease vitligo.

31 May 2012

Stiefel to acquire WBI-1001 licensing rights from Welichem

Stiefel, a GSK company, and Welichem Biotech Inc., have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.

31 May 2012

Intensive exercise answer to psoriasis prevention

Vigorous physical activity may reduce a person’s risk for developing psoriasis, show results from a US study.

30 May 2012

Intensity of itching in eczema linked to depression

Itch intensity in atopic dermatitis is related to the stress level and emotional wellbeing of patients, say researchers.

30 May 2012

FDA approves RLI’s Absorica to treat severe recalcitrant nodular acne

Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.

30 May 2012

FDA approves Cipher’s Absorica to treat severe recalcitrant nodular acne

Cipher Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.

28 May 2012

NYULMC opens new 327,000 square-foot Ambulatory Care Center

As part of its plan to expand access to a wide array of outpatient services, NYU Langone Medical Center has opened a new 327,000 square-foot Ambulatory Care Center (ACC) at 240 East 38th Street.

24 May 2012

PTH boosts AMPs to fend off infection-causing microbes

Antimicrobial peptides (AMPs) are molecules produced in the skin to fend off infection-causing microbes. Vitamin D has been credited with a role in their production and in the body's overall immune response, but scientists at the University of California, San Diego School of Medicine say a hormone previously associated only with maintaining calcium homeostasis and bone health is also critical, boosting AMP expression when dietary vitamin D levels are inadequate.

24 May 2012

Acne pills can cause eye infections

Millions of teenagers suffer from acne, and they deal with the embarrassing skin blemishes by taking popular prescription medications such as Accutane or Roaccutane. Now, however, research from Tel Aviv University shows that these pills can also cause eye infections such as conjunctivitis (pink eye) or sties.

24 May 2012

Socioeconomic factors associated with skin cancer screening

When it comes to getting screened for skin cancer, only one in 14 U.S. Hispanic adults is shown to have ever gone through the process, compared to one in four non-Hispanic white adults. Research from The Cancer Institute of New Jersey (CINJ) shows socioeconomic factors such as lack of health insurance and poorer access to healthcare serve as barriers for Hispanics who might otherwise receive this potentially lifesaving check-up.

22 May 2012